Open an account

MetaStat

MTST · OTC

$0.0544+$0.0544 (+0.00%)TodayMarket closed ·
No price history for this range.

About MTST

MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The firm's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.

Employees
0
Headquarters
Boston, Massachusetts
Listed
Feb 13, 2008
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
metastat.com

MTST key statistics

Market cap
319.71K
Price-earnings ratio
—
Dividend yield
—
Average volume
6.10K
Volume
200
Open price
$0.0544
High today
$0.0544
Low today
$0.0544
52 Week high
$0.0544
52 Week low
$0.0003

MetaStat (MTST) at a glance

As of Sep 2, 2026, MetaStat (MTST) shares are priced at $0.0544, giving the company a market cap of 319.71K.

Volume so far is 200 shares, below the average of 6.10K shares a day.

Over the past year MetaStat has ranged from $0.0003 to $0.0544, and now sits 100% of the way up that range.

MetaStat met or beat analyst EPS estimates in 2 of the last 4 quarters. In Q3 FY16 it reported -$0.72 per share against an estimate of -$0.918.

MTST earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 4 quarters, by 31.4% on average.

  1. Q4 FY13: reported -$0.45 per share against an estimate of -$0.765
  2. Q1 FY14: reported -$1.95 per share against an estimate of -$0.306
  3. Q2 FY14: reported -$0.90 per share against an estimate of -$0.459
  4. Q3 FY16: reported -$0.72 per share against an estimate of -$0.918

Similar companies

Companies in the same industry as MetaStat

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.